1
|
Swamy JM, Naik MG, Rathore SS, Srinivasa KH, Monica KS. Dietary supplementation of Nile tilapia (Oreochromis niloticus) diets with bay laurel (Laurus nobilis): alleviation of oxidative stress and amelioration of immune response, serum biochemistry, and resistance against Aeromonas hydrophila. FISH PHYSIOLOGY AND BIOCHEMISTRY 2024; 50:197-208. [PMID: 37450203 DOI: 10.1007/s10695-023-01210-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Accepted: 06/22/2023] [Indexed: 07/18/2023]
Abstract
Herbal plants can enhance immunity and alleviate oxidative stress in fish. Therefore, the present work was performed to evaluate the effects of bay laurel (Laurus nobilis) on growth, immunity, antioxidant activities, disease resistance, and hematology in Nile tilapia (Oreochromis niloticus). A total of 225 Nile tilapia fingerlings (average weight 15.36 ± 0.04 g) were divided into five treatment groups and fed with bay laurel at 0, 10, 15, 20, and 25 g/kg diet for 90 days. A completely randomized design with three replications was applied. The significantly (p < 0.05) improved weight growth (WG), food conversion ratio (FCR), average daily growth (ADG), protein efficiency ratio (PER), and survival rate were observed in fish fed with bay laurel-supplemented diet at the rate of 15 g/kg. Significantly improved red blood cells (RBCs) count, white blood cells (WBCs), hemoglobin (Hb), and significantly declined alanine aminotransaminase (ALT) and aspartate transaminase (AST) were found in the same diet-fed group. The immune response parameters such as nitro blue tetrazolium (NBT), lysozyme activity, phagocytic activity, total serum protein, serum albumin, serum globulin, and albumin-globulin ratio were found significantly improved at 15 g/kg bay laurel supplemented diet. The improved antioxidant response (catalase, glutathione peroxidase, malondialdehyde, total antioxidant activity) was also observed in the same diet-fed group. Relative percent survival after the fish challenged against Aeromonas hydrophila was significantly (p < 0.05) different. Overall, bay laurel supplementation at a 15 g/kg diet improved the nutritional physiology and immunity and, therefore, could be a potential growth-promoting feed additive for aquaculture development.
Collapse
Affiliation(s)
- Jayashri Mahadev Swamy
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, 575002, Karnataka, India
| | - M Ganapathi Naik
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, 575002, Karnataka, India
| | - Sanjay Singh Rathore
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, 575002, Karnataka, India.
| | - K H Srinivasa
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, 575002, Karnataka, India
| | - K S Monica
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, 575002, Karnataka, India
| |
Collapse
|
2
|
Rathore SS, Murthy HS, Mamun MAA, Nasren S, Rakesh K, Kumar BTN, Abhiman PB, Khandagale AS. Nano-selenium Supplementation to Ameliorate Nutrition Physiology, Immune Response, Antioxidant System and Disease Resistance Against Aeromonas hydrophila in Monosex Nile Tilapia (Oreochromis niloticus). Biol Trace Elem Res 2021; 199:3073-3088. [PMID: 33025518 DOI: 10.1007/s12011-020-02416-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Accepted: 09/30/2020] [Indexed: 10/23/2022]
Abstract
In the present work, a total 180 monosex male Nile tilapia fingerlings (15.73 ± 0.05 g) were stocked in 150-l FRP tanks categorised into four diet groups with triplicate each and fed with dietary nano-selenium-supplemented diets at different concentration (T1-0, T2-0.5, T3-1.0 and T4-2.0 mg/kg of feed) for 90 days and different nutrition physiological parameters (feed utilization, haematology, serum biochemistry), immune response and antioxidant were analysed during pre- and post-challenge against Aeromonas hydrophila. The study results depicted that significantly (p < 0.05) better growth and feed utilization (absolute weight gain, specific growth rate, average daily gain, protein efficiency ratio, food conversion ratio) found in fish fed diet supplemented with 1 mg/kg of nano-Se. Significantly (p < 0.05) improved haematological (red blood cells, haemoglobin, white blood cells, platelets) and serum biochemical parameters (alanine aminotransferase, aspartate aminotransferase, glucose, cholesterol, triglycerides) observed in the same diet group. The same trend was followed by immune parameters (nitro blue tetrazolium, lysozyme activity, myeloperoxidase, total immunoglobulin). Also observed the statistically (p < 0.05) improved antioxidant activities (catalase, superoxide dismutase, glutathione peroxides, glutathione reductase, glutathione S-transferase, malondialdehyde, total antioxidant capacity) in the same diet group. Relative percent survival after the fishes challenged with A. hydrophila was significantly (p < 0.05) differed. The findings suggested that supplementation of 1 mg/kg of dietary nano-Se could able to ameliorate nutrition physiology, immunity, antioxidant activity and disease resistance in tilapia and proved that it may be one of the best element for fish farmers to increase the production in an economically feasible way.
Collapse
Affiliation(s)
- Sanjay Singh Rathore
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, Karnataka, 575002, India.
- Department of Aquaculture, College of Fisheries, Chhattisgarh Kamdhenu Vishwavidyalaya, Kawardha, Chhattisgarh, 491995, India.
| | - Hanumappa Shivananda Murthy
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, Karnataka, 575002, India
| | - Muhammad Abdullah-Al Mamun
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, Karnataka, 575002, India
| | - Shamima Nasren
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, Karnataka, 575002, India
| | - Kalyani Rakesh
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, Karnataka, 575002, India
| | - Billekallu Thammegowda Naveen Kumar
- Department of Aquatic Environment, College of Fisheries, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, 141004, India
| | - Purandara Ballyaya Abhiman
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, Karnataka, 575002, India
| | - Ajay Sathayanarayan Khandagale
- Department of Aquaculture, College of Fisheries, Karnataka Veterinary, Animal and Fisheries Sciences University, Mangalore, Karnataka, 575002, India
| |
Collapse
|
3
|
Chan P, Wong W, Wong K, Cheng I, Chan M. Lupus Nephritis Patients on Maintenance Dialysis in Hong Kong. Int J Artif Organs 2018. [DOI: 10.1177/039139888901201209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Eleven patients with lupus nephritis required maintenance dialysis. Two were on haemodialysis (HD), 9 on continuous ambulatory peritoneal dialysis (CAPD). One was subsequently transplanted and recurrence of lupus nephritis occurred at 9 months post-transplant. One discontinued CAPD after 6 months; 4 died and the remaining 7 were fully rehabilitated. There was marked regression of extra-renal lupus activity post-dialysis
Collapse
Affiliation(s)
- P.C.K. Chan
- Department of Medicine, University of Hong Kong, Queen Mary Hospital - Hong Kong
| | - W.S. Wong
- Department of Medicine, University of Hong Kong, Queen Mary Hospital - Hong Kong
| | - K.L. Wong
- Department of Medicine, University of Hong Kong, Queen Mary Hospital - Hong Kong
| | - I.K.P. Cheng
- Department of Medicine, University of Hong Kong, Queen Mary Hospital - Hong Kong
| | - M.K. Chan
- Department of Medicine, University of Hong Kong, Queen Mary Hospital - Hong Kong
| |
Collapse
|
4
|
Yap KS, Urowitz MB, Mahood Q, Medina-Rosas J, Sabapathy A, Lawson D, Su J, Gladman DD, Touma Z. The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. Semin Arthritis Rheum 2017; 46:791-797. [PMID: 27769590 DOI: 10.1016/j.semarthrit.2016.09.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Revised: 09/13/2016] [Accepted: 09/14/2016] [Indexed: 11/25/2022]
|
5
|
Lionaki S, Skalioti C, Boletis JN. Kidney transplantation in patients with systemic lupus erythematosus. World J Transplant 2014; 4:176-182. [PMID: 25346890 PMCID: PMC4208080 DOI: 10.5500/wjt.v4.i3.176] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2013] [Revised: 04/24/2014] [Accepted: 07/17/2014] [Indexed: 02/05/2023] Open
Abstract
Despite improvements in overall prognosis in lupus nephritis, 10%-30% of patients with proliferative renal involvement progress to end stage renal disease, according to the severity of the disease and associated socioeconomic factors. Kidney transplantation has been recognized as the most appropriate treatment for those patients, but several issues remain after renal function restoration in a lupus recipient. Among these are the fear of lupus nephritis recurrence in the graft, the choice of immunosuppressive therapy in cases of recurrent lupus for a patient who has already received a toxic and prolonged immunosuppressive course, and finally, the management of comorbidities to reduce associated morbidities in the long term. All the above topics are examined in this review, with the hope of providing a clear picture of data as illustrated in the current literature.
Collapse
|
6
|
Ding Y, Liu X, Bu L, Li H, Zhang S. Antimicrobial-immunomodulatory activities of zebrafish phosvitin-derived peptide Pt5. Peptides 2012; 37:309-13. [PMID: 22841856 DOI: 10.1016/j.peptides.2012.07.014] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Revised: 07/18/2012] [Accepted: 07/18/2012] [Indexed: 02/04/2023]
Abstract
A phosvitin (Pv)-derived peptide, Pt5, which consists of the C-terminal 55 residues of Pv in zebrafish, has been shown to function as an antimicrobial agent capable of killing microbes in vitro. However, its in vivo role in zebrafish remains unknown. In this study, we clearly demonstrated that Pt5 protected adult zebrafish from pathogenic Aeromonas hydrophila attack, capable of significantly enhancing the survival rate of zebrafish after the pathogenic challenge. Pt5 also caused a marked decrease in the numbers of A. hydrophila in the blood, spleen, kidney, liver and muscle, suggesting that Pt5 was able to block multiplication/dissemination of A. hydrophila in zebrafish. Additionally, Pt5 markedly suppressed the expression of the proinflammatory cytokine genes IL-1β, IL-6, TNF-α and IFN-γ in the spleen and head kidney of A. hydrophila-infected zebrafish, but it considerably enhanced the expressions of the antiinflammatory cytokine genes IL-10 and IL-4 in the same tissues. Taken together, these data indicate that Pt5 plays a dual role in zebrafish as an antimicrobial and immunomodulatory agent, capable of protecting zebrafish against pathogenic A. hydrophila through its antimicrobial activity as well as preventing zebrafish from the detrimental effects of an excessive inflammatory response via modulating immune functions.
Collapse
Affiliation(s)
- Yunchao Ding
- Laboratory for Evolution & Development, Institute of Evolution & Marine Biodiversity and Department of Marine Biology, Ocean University of China, Qingdao 266003, China
| | | | | | | | | |
Collapse
|
7
|
Oliveira CS, d Oliveira I, Bacchiega ABS, Klumb EM, Albuquerque EMM, Souza E, Suassuna JHS, Ribeiro FM. Renal transplantation in lupus nephritis: a Brazilian cohort. Lupus 2011; 21:570-4. [PMID: 22129601 DOI: 10.1177/0961203311430220] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To determine the epidemiological profile and outcome of patients with lupus nephritis (LN) undergoing renal transplantation. METHODS The archival records of 50 patients with LN and end-stage renal disease (ESRD) treated by kidney transplantation from March 1992 to December 2010 were reviewed. All patients met the American College of Rheumatology criteria for systemic lupus erythematosus (SLE). RESULTS Fourteen patients were included in the study. The majority were women (85.7%) and non-Caucasian (85.7%); the mean age at diagnosis of SLE and LN was 24 ± 8 and 25 ± 8 years, respectively. Renal biopsy was performed in 12 patients, with 75% of them showing proliferative lesions (class III and IV according to the World Health Organization and International Society of Nephrology/Renal Pathology Society classification). Thirteen patients (93%) underwent intermittent hemodialysis or peritoneal dialysis before transplantation. The median time between the start of dialysis and transplantation was 30 months (range 3-103 months); 67% of the procedures involved deceased donors and 33% involved living-related donors. The graft survival rates were 93.3%, 90.9%, and 85.7% at 1, 5 and 10 years, respectively. Post-transplant immunosuppressive agents were mycophenolate mofetil (84%), azathioprine (17%), tacrolimus (25%), sirolimus (58%) and cyclosporine (8%). Eight episodes of acute rejection were noted in six patients. There was a graft loss due to renal vein thrombosis in the one patient with secondary antiphospholipid syndrome. The mean SLICC by the time of kidney transplantation was 5 ± 2. In total, 13 patients (92.8%) developed at least one infectious event during the follow-up, with one dying in the immediate post-transplant period because of sepsis. Two patients (14%) had a lupus flare. There was no clinical or histological evidence of LN recurrence. CONCLUSION LN is the major cause of morbidity in SLE, with progression to ESRD in 10-22% of cases. Despite concerns about LN recurrence after renal transplantation, the data obtained in our sample indicate this procedure as a safe alternative therapy for ESRD in this population.
Collapse
Affiliation(s)
- C S Oliveira
- Disciplina de Reumatologia, Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Contreras G, Mattiazzi A, Guerra G, Ortega LM, Tozman EC, Li H, Tamariz L, Carvalho C, Kupin W, Ladino M, LeClercq B, Jaraba I, Carvalho D, Carles E, Roth D. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol 2010; 21:1200-7. [PMID: 20488956 DOI: 10.1681/asn.2009101093] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The frequency and outcome of recurrent lupus nephritis (RLN) among recipients of a kidney allograft vary among single-center reports. From the United Network for Organ Sharing files, we estimated the period prevalence and predictors of RLN in recipients who received a transplant between 1987 and 2006 and assessed the effects of RLN on allograft failure and recipients' survival. Among 6850 recipients of a kidney allograft with systemic lupus erythematosus, 167 recipients had RLN, 1770 experienced rejection, and 4913 control subjects did not experience rejection. The period prevalence of RLN was 2.44%. Non-Hispanic black race, female gender, and age <33 years each independently increased the odds of RLN. Graft failure occurred in 156 (93%) of those with RLN, 1517 (86%) of those with rejection, and 923 (19%) of control subjects without rejection. Although recipients with RLN had a fourfold greater risk for graft failure compared with control subjects without rejection, only 7% of graft failure episodes were attributable to RLN compared and 43% to rejection. During follow-up, 867 (13%) recipients died: 27 (16%) in the RLN group, 313 (18%) in the rejection group, and 527 (11%) in the control group. In summary, severe RLN is uncommon in recipients of a kidney allograft, but black recipients, female recipient, and younger recipients are at increased risk. Although RLN significantly increases the risk for graft failure, it contributes far less than rejection to its overall incidence; therefore, these findings should not keep patients with lupus from seeking a kidney transplant.
Collapse
Affiliation(s)
- Gabriel Contreras
- Division of Nephrology, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
McGrory CH, McCloskey LJ, DeHoratius RJ, Dunn SR, Moritz MJ, Armenti VT. Pregnancy outcomes in female renal recipients: a comparison of systemic lupus erythematosus with other diagnoses. Am J Transplant 2003; 3:35-42. [PMID: 12492708 DOI: 10.1034/j.1600-6143.2003.30107.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
This study compares pregnancy outcomes in systemic lupus erythematosus (SLE) patients post renal transplant with recipients with other primary diagnoses, utilizing data from the National Transplantation Pregnancy Registry, Philadelphia, PA. Recipients were referred from transplant centers nationwide. A retrospective analysis was performed using data from questionnaires, hospital records and telephone interviews. Outcomes of pregnancies post renal transplant secondary to lupus nephritis (SLE: n = 38; 60 pregnancies) were compared with the pregnancy outcomes of renal recipients with other diagnoses (non-SLE: n = 247; 374 pregnancies). Drug-treated hypertension during pregnancy was less common in the SLE group than in the non-SLE group (45.0% vs. 62.5%, p = 0.015). There were fewer cesarean sections in the SLE group (30.2 vs. 53.2%, p = 0.008). There was no primary or gestational diabetes in the SLE group. There were no other statistical differences in maternal conditions or pregnancy outcomes between the SLE and non-SLE groups, or in the incidence of post pregnancy graft loss. Female recipients transplanted for renal failure secondary to lupus nephritis can successfully maintain pregnancy. Outcomes are comparable to renal recipients with other diagnoses. Newborns in both groups were often premature and had low birthweight. Overall childhood health was reported to be good; there were no apparent predominant structural malformations among the children.
Collapse
Affiliation(s)
- Carolyn H McGrory
- Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
| | | | | | | | | | | |
Collapse
|
10
|
Mengel M, Kreipe H, Haller H, Schwarz A. Recurrent lupus nephritis in a rejected renal allograft. Nephrology (Carlton) 2002. [DOI: 10.1046/j.1440-1797.2002.00096.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
11
|
Affiliation(s)
- S Hariharan
- Department of Medicine, Medical College of Wisconsin, Milwaukee 53226, USA.
| |
Collapse
|
12
|
Hashemi V, Nadjafi I, Azzordegan F, Ghahramani N, Broumand B. Renal transplantation in systemic lupus erythematosus: a multicenter study with 37 patients in Iran. Transplant Proc 1999; 31:3142-3. [PMID: 10616413 DOI: 10.1016/s0041-1345(99)00756-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- V Hashemi
- Shariati Hospital, Tehran University of Medical Sciences, Iran
| | | | | | | | | |
Collapse
|
13
|
Grimbert P, Frappier J, Bedrossian J, Legendre C, Antoine C, Hiesse C, Bitker MO, Sraer JD, Lang P. Long-term outcome of kidney transplantation in patients with systemic lupus erythematosus: a multicenter study. Groupe Cooperatif de Transplantation d'île de France. Transplantation 1998; 66:1000-3. [PMID: 9808482 DOI: 10.1097/00007890-199810270-00006] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The outcome of 60 renal transplantations in 53 patients with end-stage renal disease (ESRD) because of lupus nephritis was studied retrospectively and compared with 106 controls matched for age, sex, maximum panel-reactive antibody (PRA) level, and date of transplantation. METHODS The patients received their transplants over a 260-month period (21.5 years) between October 1971 and August 1993. The population was predominantly women (90%), and the mean age at the time of the transplantation was 33.2 years (range: 21-54 years). Fifty-six transplants (93%) were from cadaveric donors, and 4 (7%) were from living-related donors; 46 patients (86%) had primary allografts, and 7 (14%) received a second allograft. The duration of disease before transplantation was 93.6+/-6.2 months, and the duration of dialysis before transplantation was 48+/-6 months. RESULTS No patient had clinically active systemic lupus erythematosus (SLE) at the time of transplantation. The 1-year graft and patient survival rates were 83% and 98%, and the 5-year graft and patient survival rates were 69% and 96%. Actuarial graft and patient survival rates in SLE patients were not significantly different from those of the matched control group. Chronic rejection was the major risk factor for graft loss. Lupus nephritis recurred in the graft of one patient 3 months after transplantation, and there were extrarenal manifestations of SLE in four others. CONCLUSIONS The present study confirms that patients with SLE can receive transplants with excellent graft and patient survival rates and a low rate of clinical recurrent lupus nephritis.
Collapse
Affiliation(s)
- P Grimbert
- Nephrology Department, Hôpital Henri Mondor, Créteil, France
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Stone JH, Millward CL, Olson JL, Amend WJ, Criswell LA. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. ARTHRITIS AND RHEUMATISM 1998; 41:678-86. [PMID: 9550477 DOI: 10.1002/1529-0131(199804)41:4<678::aid-art15>3.0.co;2-7] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To determine the frequency of recurrent lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE) who underwent renal transplantation. METHODS We reviewed the posttransplant clinical course and renal biopsy results in 97 consecutive SLE patients who underwent a total of 106 renal transplantation procedures at our center from January 1984 to September 1996. RESULTS There were 81 female and 16 male patients, with a mean age of 35 years. Mean duration of dialysis prior to transplantation was 33.5 months; 9 patients were never dialyzed. In all patients, the disease was clinically and serologically quiescent at the time of transplantation. The mean posttransplantation followup period was 62.6 months. Patients underwent a total of 143 posttransplant biopsies. Nine patients had pathologic evidence of recurrent LN. Six of the patients with recurrence had cadaveric grafts, 2 had living-related grafts, and 1 had a living-unrelated graft. Recurrence occurred an average of 3.1 years after transplantation; the longest interval was 9.3 years and the shortest, 5 days. Histopathologic diagnoses on recurrence included diffuse proliferative glomerulonephritis, focal proliferative glomerulonephritis, membranous glomerulonephritis, and mesangial glomerulonephritis. In 4 patients, recurrent LN contributed to graft loss. Three of the patients with recurrence had serologic evidence of active lupus, but only 1 had symptoms of active lupus (arthritis). Three patients who lost their grafts secondary to recurrent LN underwent second renal transplantation procedures and had functioning grafts at 7, 30, and 35 months, respectively. CONCLUSION In the largest single medical center series of renal transplant patients with SLE, recurrent LN was more common than reported in the literature, but was not always associated with allograft loss. Recurrent LN was often present in the absence of clinical and serologic evidence of active SLE.
Collapse
Affiliation(s)
- J H Stone
- Rosalind Russell Arthritis Center, University of California, San Francisco, USA
| | | | | | | | | |
Collapse
|
15
|
Grimbert P, Lang P, Frappier J, Bedrossian J, Legendre C, Hiesse C, Bitker MO, Sraer JD, Antoine C. Renal transplantation in patients with systemic lupus erythematosus: a multicenter study. Transplant Proc 1997; 29:2363-4. [PMID: 9270765 DOI: 10.1016/s0041-1345(97)00404-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- P Grimbert
- Service de néphrologie et de transplantation rénale, Hopital Henri Mondor, Creteil, France
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Haubitz M, Kliem V, Koch KM, Nashan B, Schlitt HJ, Pichlmayr R, Brunkhorst R. Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 1997; 63:1251-7. [PMID: 9158017 DOI: 10.1097/00007890-199705150-00010] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND In patients with autoimmune diseases such as vasculitis or systemic lupus erythematosus (SLE), end-stage renal disease develops in a high percentage of patients, and kidney transplantation has become a therapeutic option. However, only limited data about the prognosis and outcome after kidney transplantation are available. METHODS Long-term graft survival and graft function of renal transplant recipients with SLE, Wegener's granulomatosis, microscopic polyangiitis, Goodpasture's syndrome, and Henoch-Schonlein purpura were evaluated in a single center. In addition, the incidence of renal and extrarenal relapses and the impact of the immunosuppressive therapy on the course of the autoimmune disease were studied. RESULTS Renal transplant recipients with autoimmune diseases such as vasculitis and SLE had a patient survival rate (94% after 5 years) and a graft survival rate (65% after 5 years) comparable to those of patients with other causes of end-stage renal disease (patient survival 88% and graft survival 71% after 5 years). Graft losses due to the underlying disease were rare. Extrarenal relapses occurred in three patients with Wegener's granulomatosis, one patient with microscopic polyangiitis, and three patients with SLE, but were less frequent compared with the period with chronic dialysis therapy. Autoantibody levels in patients with SLE, Wegener's granulomatosis, or microscopic polyangiitis did not seem to influence the outcome. CONCLUSIONS Renal transplantation should be offered to patients with autoimmune diseases. Follow-up should include the short-term control of renal and extrarenal disease activity.
Collapse
Affiliation(s)
- M Haubitz
- Department of Nephrology, Medical School Hannover, Germany
| | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
OBJECTIVE To provide an overview of the course of systemic lupus erythematosus (SLE) following the onset of end-stage lupus nephropathy, regarding clinical and serological manifestations, survival on dialysis, and renal transplant outcomes. METHODS A review of the pertinent literature, identified by a comprehensive Grateful Med search, was performed. RESULTS There is a tendency for decreased clinical and serological lupus activity following the onset of end-stage renal disease. The pathophysiology of this quiescence remains unclear. Survival of lupus patients on dialysis is no different from that of non-SLE dialysis patients, and is better than that of several other rheumatic diseases. Following renal transplantation, there is no difference in patient or graft survival in lupus versus nonlupus patients. Like their nonlupus counterparts, SLE transplant patients do better with living relative grafts and/or regimens containing cyclosporin A. Transplantation is not recommended within 3 months of the initiation of dialysis to allow possible recovery from the acute renal failure. Transplantation during an acute exacerbation of SLE is controversial, and may increase the risk of poor outcomes. Recurrence of lupus in transplanted allografts, often with the same histopathology as in the native kidney, occurs at a rate (2.7% to 3.8%) comparable to that for all allograft transplant failures (2% to 4%). CONCLUSIONS End-stage lupus nephropathy patients require less medication owing to decreased disease activity. They are good candidates for dialysis and renal transplantation, with survival and recurrence rates no different from those of other patients with end-stage renal disease.
Collapse
Affiliation(s)
- C F Mojcik
- National institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | |
Collapse
|
18
|
Lochhead KM, Pirsch JD, D'Alessandro AM, Knechtle SJ, Kalayoglu M, Sollinger HW, Belzer FO. Risk factors for renal allograft loss in patients with systemic lupus erythematosus. Kidney Int 1996; 49:512-7. [PMID: 8821838 DOI: 10.1038/ki.1996.73] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Controversy exists regarding the risk factors for renal allograft loss in patients with systemic lupus erythematosus (SLE). This study is a retrospective evaluation of each of these independent risk factors in 80 renal transplants for ESRD secondary to SLE done at our institution between 1971 and 1994. Our entire non-diabetic cohort of 1,966 renal transplants is used as a comparison group. Our results showed equivalent graft survival rates between lupus patients and the cohort at 1, 5 and 10 years (P = 0.56). However, an analysis of cyclosporine-era cadaver grafts revealed that the lupus group had poorer 5-year graft survival than the cohort (41% vs. 71%, P = 0.02). Evaluation of cyclosporine-era lupus graft survival showed significantly improved outcome in living-related lupus recipients over cadaver grafts at five years (89% vs. 41%, P = 0.003). The majority of grafts lost in the lupus cadaver recipients were due to chronic rejection. Rejection was increased in lupus recipients: 69% of lupus patients experienced rejection in the first year compared to 58% of controls (P = 0.01). Stratified for age, sex, race and cyclosporine use, this difference remained significant (P = 0.003, relative risk 1.7). Nephrectomy, splenectomy and 3 to 6 months of pretransplant dialysis did not improve graft survival. A dialysis duration of greater than 25 months predicted worse graft survival (P = 0.01). Among lupus patients, PRA did not correlate with graft outcome (P = 0.5), and HLA-identical cadaver grafts had improved outcomes compared to cadaver grafts. We conclude that acute and chronic rejection are the major risk factors for graft loss in lupus patients. The superior outcome of living-related over cadaver grafts in lupus patients suggests an increased role for living-related grafts. Pretransplant dialysis, nephrectomy and splenectomy are not indicated.
Collapse
Affiliation(s)
- K M Lochhead
- Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, USA
| | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Renal transplantation in children is a most rewarding treatment that dramatically changes the overall health and lifestyle of children with ESRD. Complexities in different aspects of renal transplantation in children are obvious. Optimum technical conditions and drug therapy must be provided for the success of renal transplantation. Application of recent advances in immunology and long-term care to clinical transplantation continue to improve graft and patient survival rates. Optimization of growth and development also can be improved with the use of rhGH.
Collapse
Affiliation(s)
- G Bereket
- Department of Pediatrics, State University of New York at Stony Brook, USA
| | | |
Collapse
|
20
|
Revelo MP, Pereira MV, Nogueira TS, Bambirra EA. Recurrence of lupus nephritis in a renal allograft with histological transformation of the lesion. Histopathology 1995; 26:292-3. [PMID: 7797209 DOI: 10.1111/j.1365-2559.1995.tb01449.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
21
|
Abstract
Virtually all diseases affecting the native kidney recur in the kidney transplant with the exception of Alport syndrome, polycystic kidney disease, hypertension, chronic pyelonephritis, and chronic interstitial nephritis. Fortunately, in the majority of patients, recurrence of the original disease has minimal clinical impact, with only approximately 5% of all graft loss occurring as a result of recurrent disease. The primary renal diseases that commonly recur include membranoproliferative glomerulonephritis type II, IgA nephropathy, and focal and segmental glomerular sclerosis. The most common systemic disease that recurs is diabetic nephropathy. Living-related transplantation should be used with caution in patients with the hemolytic uremic syndrome, recurrent focal and segmental glomerular sclerosis, and membraneous glomerulonephritis. Fabry disease and primary hyperoxaluria type I are no longer absolute contraindications to kidney transplantation.
Collapse
Affiliation(s)
- E L Ramos
- Department of Medicine, University of Florida, Gainesville 32610-0224
| | | |
Collapse
|
22
|
Ward LA, Jelveh Z, Feinfeld DA. Recurrent membranous lupus nephritis after renal transplantation: a case report and review of the literature. Am J Kidney Dis 1994; 23:326-9. [PMID: 8311095 DOI: 10.1016/s0272-6386(12)80992-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Recurrent lupus nephritis in transplanted kidneys is rare. To the best of our knowledge, we report only the second case of recurrent membranous lupus nephritis in an allograft 8 years after transplantation. Unlike the first case, our patient received a transplant from a living-related donor rather than a cadaver. Disease "burn-out," the use of immunosuppressive drugs, and treatment of recurrence as rejection have all been offered as possible explanations for the rarity of recurrence. The majority of cases represent recurrence of the proliferative lesions, although a variety of histologic patterns and transformations have been reported.
Collapse
Affiliation(s)
- L A Ward
- Department of Medicine, Nassau County Medical Center, East Meadow, NY 11554
| | | | | |
Collapse
|
23
|
Abstract
The progression of lupus nephritis severe enough to require dialysis does not necessarily indicate that it is "end-stage." Ten percent to 28% of patients with lupus nephritis who develop renal failure requiring dialysis will recover enough function to come off dialysis. The clinical activity of systemic lupus erythematosus (SLE) is quiescent in most patients with end-stage lupus nephritis, regardless of the modality of dialysis treatment. Clinical and serologic remission of SLE permits judicious withdrawal of immunosuppressive therapy, as well as a favorable long-term outcome for patients that is comparable to that of nonlupus patients. The great majority of deaths in patients with end-stage lupus nephritis occur in the first 3 months of dialysis and most often result from infection. Later, infection and cardiovascular complications are common causes of death. Patients with lupus nephritis should wait at least 3 months on dialysis before receiving a kidney transplantation. Immunosuppressive therapy and graft survival rates for lupus patients are not different from those of nonlupus patients. Recurrence of lupus nephritis in the allograft is exceedingly rare.
Collapse
Affiliation(s)
- J S Cheigh
- Rogosin Kidney Center, New York Hospital, Cornell University Medical College, NY 10021
| | | |
Collapse
|
24
|
Fox L, Zager PG, Harford AM, Tung KS, Smith SM. Lupus nephritis in a pediatric renal transplant recipient. Pediatr Nephrol 1992; 6:467-9. [PMID: 1457330 DOI: 10.1007/bf00874017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A case of aggressive lupus nephritis in a pediatric renal transplant patient is described. She initially presented with end-stage glomerulonephritis for which an underlying etiology could not be determined. Ten months after cadaveric renal transplantation, systemic lupus erythematosus was diagnosed, when she developed diffuse proliferative glomerulonephritis in association with antinuclear antibody, anti-double-stranded DNA antibody and extrarenal manifestations of lupus. It is plausible that she developed recurrent rather than de novo lupus nephritis following transplantation. Reactivation of lupus nephritis in a renal transplant is unusual in adults, and is previously unreported in children.
Collapse
Affiliation(s)
- L Fox
- Department of Medicine, University of New Mexico School of Medicine, Albuquerque 87131
| | | | | | | | | |
Collapse
|
25
|
|
26
|
Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, Riggio RR, Rubin AL. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990; 16:189-95. [PMID: 2399912 DOI: 10.1016/s0272-6386(12)81017-1] [Citation(s) in RCA: 59] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We studied the clinical course of 59 lupus patients with end-stage renal disease (ESRD) to determine their long-term prognosis and delineate the evolution of their lupus activity. The study population was predominantly female (86%) and young (mean age, 27.4 years), and they were observed for a mean of 6.5 years from the inception of dialysis. At the time dialysis was initiated, only 21 patients (35.6%) had clinically active systemic lupus erythematosus (SLE). The remaining patients progressed to ESRD despite the absence of clinical lupus activity. Lupus activity was clinically apparent in 55.4% of patients in the first year, 6.5% in the fifth, and none in the tenth year. In 45% of patients, lupus activity was clinically inactive at entry to ESRD and remained inactive throughout the observation period. Serological activity declined proportionally, but to a lesser extent than clinical activity. Cumulative patient survival was 81.1% and 74.6% at the fifth and tenth year, respectively, from the inception of dialysis treatment; similarly it was 78% at the fifth and tenth year after the transplantation. Graft survival was 60.4% at the fifth and 45.5% at the tenth year. No one had recurrence of clinical lupus nephritis in the graft for up to 16 years of follow-up. Fourteen patients died from either infectious or cardiovascular complications, but none from SLE per se. This long-term study with a large number of lupus patients confirms our previous findings that the progression of renal disease to ESRD may be mediated by nonimmunologic mechanisms, as well as immunologic insults.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J S Cheigh
- Department of Medicine, Rogosin Kidney Center, New York Hospital/Cornell University Medical Center, NY 10021
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
The diagnosis of recurrent renal disease after transplantation is dependent on an accurate and complete diagnosis of the initial cause of renal failure and a similar determination of the cause of graft failure. To be classified as recurrent, the disease in the renal graft must be identical to that seen in the native kidneys. Recurrence of disease accounts for less than 2% of all graft failures, but the overall incidence of recurrent disease is probably 5 to 10 times more common. The most frequent cause of recurrent disease is glomerulonephritis, which was first recognized to recur soon after renal transplantation was introduced. It was then recognized that a variety of metabolic disorders would recur, but it has taken 25 years of experience for a clear picture to emerge of recurrence in most conditions. No initial cause of renal failure poses a contraindication to at least one attempt at transplantation, although with Fabry's disease and oxalosis, a special assessment of the risks for the individual recipient is warranted. In some patients, experience has shown the need for a delay in the commitment to transplantation (eg, in those with anti-glomerular basement membrane [GBM] antibody glomerulonephritis or Henoch Schonlein purpura), the need for the choice of a particular immunosuppressive regimen (eg, in hemolytic uremic syndrome [HUS]), the need for avoidance of primary nonfunction (eg, in oxalosis), and the desirability of avoiding live kidney donation (eg, in heterozygote donors in Fabry's disease, high-risk recipients with focal glomerulosclerosis, and in recipients with HUS). Probably all types of glomerulonephritis recur, but with great variation in frequency and severity. In some forms of glomerulonephritis, recurrence may be frequent and definite on histopathological criteria but may only have a minor clinical expression (eg, dense deposit disease, anti-GBM antibody glomerulonephritis, IgA nephropathy), but in others, recurrence is less predictable yet it is clearly associated with premature graft failure (eg, focal glomerulosclerosis, membranous nephropathy). A common theme emerging is that where the initial glomerulonephritis is aggressive and causes kidney failure over a short time, recurrence is more likely, and when present, it will lead to graft failure with an increased frequency. Clinical manifestations, the frequency of recurrence, and the prognosis of the graft are now identified for most conditions. Unexpected observations have included the rarity of recurrent systemic lupus erythematosus (SLE), the immediate return of heavy proteinuria in focal glomerulosclerosis, and the predictable return of dense deposit disease.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- T H Mathew
- Renal Unit, Queen Elizabeth Hospital, Woodville South, South Australia
| |
Collapse
|
28
|
Gradus DB, Fine RN. Recent developments in dialysis and transplantation. Indian J Pediatr 1988; 55:559-73. [PMID: 3049336 DOI: 10.1007/bf02868439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
29
|
|
30
|
Medical Aspects of Renal Transplantation. Clin Transplant 1987. [DOI: 10.1007/978-94-009-3217-3_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
31
|
|
32
|
Correia P, Cameron JS, Lian JD, Hicks J, Ogg CS, Williams DG, Chantler C, Haycock DG. Why do patients with lupus nephritis die? BRITISH MEDICAL JOURNAL 1985; 290:126-31. [PMID: 3917713 PMCID: PMC1415465 DOI: 10.1136/bmj.290.6462.126] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Over 20 years 42 of 138 patients with systemic lupus erythematosus "died"--that is, suffered actual death or went into terminal renal failure, or both; data from 41 were available for analysis. In most patients the causes of death were multiple. Twenty seven patients went into terminal renal failure, of whom 25 were offered dialysis treatment. Three regained renal function later, 12 survived on dialysis or with functioning kidney allografts--almost all with inactive lupus--but 13 died after starting dialysis, most within a few weeks or months. The principal causes were active lupus or infection. In those patients with renal failure after rapid deterioration in renal function (n = 14) there were nine deaths, while of 10 patients with a slow evolution into renal failure, only four died. Four patients with impaired and 10 with normal renal function died, again most often from complications of lupus or from infection. Vascular disease was a major cause of death in seven patients, all but two of whom were young; of 15 postmortem examinations, eight showed severe coronary artery atheroma, and three surviving patients required coronary bypass operations. Analysis of the timing of death or entry into renal failure showed that in 12 out of 13 patients who died within two years of onset the lupus was judged to be active, while this was true in only eight out of 19 patients who died later. Six of the seven vascular deaths occurred later than two years from onset, while only nine of 26 renal "deaths" occurred before two years; deaths from infections (n = 13) were distributed equally. Despite this and aggressive treatment of active disease, the principal cause of actual death was uncontrolled lupus.
Collapse
|
33
|
Leumann EP, Briner J. [Recurrence of the original disease in the transplanted kidney]. KLINISCHE WOCHENSCHRIFT 1984; 62:289-98. [PMID: 6374274 DOI: 10.1007/bf01716444] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Recurrence of the original disease in the transplanted kidney is observed in 5.6%-9.3% of the patients. However, the clinical significance of recurrence is often minor. Diagnosis is easy in diseases with specific renal lesions, e.g., in dense deposit disease and IgA-nephropathy, but may be difficult if such a marker is missing. Recurrence is of special clinical importance in the following conditions: Membranoproliferative GN type I (in 33%, often severe) and type II (= dense deposit disease, recurrence in 90%, often minor), focal segmental glomerulosclerosis (in 48% of patients with a rapid course (less than 3 years) and in 12% of patients with a longer duration of the original disease; often severe), membranous nephropathy (recurrence rather rare, but often serious), and primary hyperoxaluria (in 100%). Mesangial IgA deposits recur in half of the patients with IgA-nephropathy and anaphylactoid purpura, but clinical findings are often minimal. Recurrence in anti-GBM-nephritis and SLE is rare. The study of recurrence may contribute to a better understanding of many renal diseases.
Collapse
|
34
|
|
35
|
|
36
|
Abstract
Nephropathies found in systemic lupus erythematosus (SLE), progressive systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, and mixed connective tissue disease are discussed. Pathogenetic insights derived from the study of kidney tissue are highlighted and clinicopathologic correlations indicated. The question of whether to perform kidney biopsy in lupus patients is also addressed.
Collapse
|
37
|
|
38
|
Coplon NS, Diskin CJ, Petersen J, Swenson RS. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 1983; 308:186-90. [PMID: 6336825 DOI: 10.1056/nejm198301273080403] [Citation(s) in RCA: 112] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
In an attempt to define the long-term clinical course of systemic lupus erythematosus followed by end-stage renal disease, we studied 28 patients with lupus nephritis at Stanford University between January 1969 and December 1980. The clinical and serologic manifestations of both renal and nonrenal disease improved with long-term hemodialysis despite the withdrawal of immunosuppressive drugs in almost all the patients. Rehabilitation was excellent, and a return to normal physical activity was generally the rule. The mortality rate was low (6 of the 28 patients died), but death occurred primarily in patients receiving high doses of prednisone. Recovery from renal failure and discontinuation of dialysis were not rare (eight patients recovered) despite the reduction in immunosuppressive drugs. Renal transplantation was also well tolerated. We found the long-term clinical course of these patients to be comparable to that of patients with end-stage renal disease associated with disorders other than systemic lupus erythematosus.
Collapse
|
39
|
|